

PATENT

41  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



IN RE APPLICATION OF )

ALEXANDER ET AL )

SERIAL NUMBER: 09/917,403 )

FILED: 27 JULY 2001 )

GROUP ART UNIT: 1616 )

EXAMINER: SABIHA NAMI QAZI )

DATE: 20 NOVEMBER 2003 )

TITLE: EPOXY STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents,  
United States Patent and Trademark Office,  
Alexandria, VA 22313-1450

on 20 NOV 03

JOSEPH R. SCHUH

Registration No. 48,180

*Joseph R. Schuh*

Date: November 20, 2003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. 1.97-1.99

Commissioner of Patents and Trademarks  
Alexandria, VA 22313-1450

Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR §1.97-1.99 and MPEP §609.

The PCT International Search Report (attached) dated September 12, 2002, listed three documents as relevant to Claims 1, 21, 22, 33, 36, 40, 42, and 47-51.

The three documents, namely:

P. Poncelet E.A.: "Spironolactone and altizide used in combination with enalapril: twenty-four-hour ambulatory recording of blood pressure", The American Journal of Cardiology, vol 65, 1990, pages 33k-35k, XP000577438, page 33K;

W.P. Leary E.A.: "Aldactone and acebutolol in treatment of hypertension", The Journal of International Medical Research, vol. 7, no 1, 1979, pages 29-32, XP008007190, pages 29-32; and

GP:-1616  
C-3355  
RECEIVED  
TECH CENTER  
DEC 01 2003


F. Nevens E.A.: "The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites: Hepatology (Baltimore), vol. 23, no 5, 1996, pages 1047-1052, XPO08007209, page 1047, are included in Document Category "X" denoted in the International Search Report as a "document of particular relevance, i.e., the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone."

Attached is a copy of the PCT International Search Report including the International Preliminary Examining Authority's comments as to the relevance of the cited documents to the claimed invention.

Copies of cited documents are enclosed herewith for the Examiner's convenience, along with PTO Form 1449 listing all documents.

Please charge any fees related to the filing of these documents to Deposit Account 19-1025.

Respectfully submitted,



Joseph R. Schuh  
Agent for Applicants  
Registration No. 48,180

PHARMACIA CORPORATION  
of Pfizer Inc.  
Corporate Patent Department  
P. O. Box 1027  
Chesterfield, MO 63006

Form PTO 1449 U.S. Department of Commerce  
(Rev. 7-80) Patent and Trademark Office

Atty. Docket No. Serial No.

C-3355 09/917,403


APPLICANT

Alexander et al.

Filing Date Group

27 July 2001 1616

LIST OF DOCUMENTS CITED BY APPLICANT  
(Use several sheets if necessary)



U. S. PATENT DOCUMENTS

* Exmr. In	Document Number	Issue Date	Name	U.S. Class	Sub Class	Filing Date

Foreign Patent Documents

Document Number	Publication Date	Country	Int. Class	Sub Class	Trans Y	N

Other Documents (Including Author, Title, Date, Pertinent Pages, etc.)

[A] F. Nevens E.A.: "The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites: **Hepatology (Baltimore)**, vol. 23, no 5, 1996, pp. 1047-1052, XPO08007209, p. 1047

[B] P. Poncelet E.A.: "Spironolactone and altizide used in combination with enalapril: twenty-four-hour ambulatory recording of blood pressure", **The American Journal of Cardiology**, vol 65, 1990, pp. 33k-35k, XP000577438, p. 33k

[C] W.P. Leary E.A.: "Aldactone and acebutolol in treatment of hypertension", **The Journal of International Medical Research**, vol. 7, no 1, 1979, pp. 29-32, XPO08007190, pp. 29-32

EXAMINER

DATE CONSIDERED

\* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
DEC 01 2003  
TECH CENTER 1600/2330